Table 2 Baseline characteristics of advanced cases in our cohort
From: The tandem duplicator phenotype may be a novel targetable subgroup in pancreatic cancer
Advanced | HRD (N = 23) | Non-BRCA1 TDP (N = 33) | Typicals (N = 283) |
|---|---|---|---|
Median age (range) | 61 (42–77) | 62 (35–77) | 64 (29–84) |
Gender | |||
Male | 13 (56%) | 23 (69.6%) | 165 (58.3%) |
Females | 10 (43%) | 10 (30.3%) | 118 (41.6%) |
Ethnicity | |||
White/Caucasian | 17 (74%) | 26 (79%) | 194 (68.5%) |
Asian | 4 (17%) | 4 (12%) | 47 (16.6%) |
Black/African/Caribbean | 2 (10%) | 0 (0%) | 7 (2.4%) |
Hispanic | 0 (0%) | 1 (3%) | 0 (0%) |
American Indian or Alaska Native | 0 (0%) | 0 (0%) | 2 (0.7%) |
Unknown | 0(0%) | 2 (6%) | 32 (8.4%) |
Others* | 0 (0%) | 0 (0%) | 1 (3.5%) |
CA19-9(Median) KU/L | 5625 (n = 20) | 3447 (n = 24) | 1299 (n = 231) |
Range | 0.8–371847 | 9–86539 | 0.8–305453 |
Sites of metastasis | n = 20 | n = 24 | n = 231 |
Liver | 17 (85%) | 19 (79%) | 162 (70%) |
Lung | 2 (10%) | 0 (0%) | 16 (6.9%) |
Omentum | 4 (20%) | 6 (25%) | 49 (21.2%) |
LN | 1 (5%) | 4 (16.6%) | 28 (12.1%) |
Clinical stage | |||
III | 0 (0%) | 8 (24.2%) | 35 (12.3%) |
IV | 23 (100%) | 25 (75.7%) | 248 (87.6%) |
Denovo/Metastatic | |||
Denovo Metastatic | 22 (95%) | 31 (94%) | 224 (79.1%) |
Recurrent | 1 (4.3%) | 2 (6%) | 21 (7.4%) |
Locally advanced unresectable | 0 (0%) | 0 (0%) | 38 (13.4%) |
First line chemotherapy | |||
n/a | 0 (0%) | 3 (9%) | 21 (7.4%) |
Folfirinox | 17 (74%) | 21 (63.6%) | 146 (51.5%) |
Gemcitabine/Cisplatin | 2 (8.7%) | 0 (0%) | 0 (0%) |
Gemcitabine/nab-Palcitaxel | 2 (8.7%) | 9 (27%) | 81 (28.6%) |
Single Agent Gemcitabine | 1 (4.3%) | 0 (0%) | 7 (2.4%) |
Clinical trial and others** | 1 (4.3%) | 0 (0%) | 28 (9.8%) |
Time on first line chemo(weeks) | 45 | 22.9 | 17 |
Range | 0–149.8 | 0–145.5 | 0–176 |
Second line chemo | n = 9 | n = 3 | N = 81 |
FOLFIRINOX | 0 (0%) | 0 (0%) | 10 (12.3%) |
Gemcitabine/Cisplatin | 5 (45%) | 0 (0%) | 0 (0%) |
Gemcitabine/nab-Paclitaxel | 1 (9%) | 0 (0%) | 17 (21%) |
Single Agent Gemcitabine | 2 (18%) | 2 (66.6%) | 17 (21%) |
5FU based chemotherapy | 0 (0%) | 0 (0%) | 9 (11.1%) |
NALIRIFOX | 0 (0%) | 0 (0%) | 8 (9.8%) |
Clinical trials and others*** | 1 (27%) | 1 (33.3%) | 20 (24.6%) |
Time on second-line chemo(weeks) | 6 | 2.7 | 7.8 |
Range | 1.4–155 | 1–17.2 | 0–107.8 |
